Patients developing AKI can now be identified early, enabling timely initiation of treatment!

Nov. 2022

The delayed diagnosis of acute kidney injury (AKI) episodes and the lack of specificity of current single AKI biomarkers hamper its management. Urinary peptidome analysis may help to identify early molecular changes in AKI and grasp its complexity to identify potential targetable molecular pathways.

Multicentric validation of diagnostic tests for bladder cancer

Oct. 2022

Non-invasive urine-based biomarkers can potentially improve current diagnostic and monitoring protocols for bladder cancer (BC). Here we assess the performance of earlier published biomarker panels for BC detection (BC-116) and monitoring of recurrence (BC-106) in combination with cytology, in two prospectively collected patient cohorts.

Predictive performance and clinical application of COV50, a urinary proteomic biomarker in early COVID-19 infection

Oct. 2022

The SARS-CoV-2 pandemic is a worldwide challenge. The CRIT-CoV-U pilot study generated a urinary proteomic biomarker consisting of 50 peptides (COV50), which predicted death and disease progression from SARS-CoV-2. After the interim analysis presented for the German Government, here, we aimed to analyse the full dataset to consolidate the findings and propose potential clinical applications of this biomarker.

Early detection of significant prostate cancer

Sept. 2022

Prostate cancer (PC) is a leading cause of morbidity and mortality among men worldwide. One major issue in PCa research is to accurately distinguish between indolent and clinically significant (csPCa) to reduce overdiagnosis and overtreatment. 

A new study was published, dealing with the validation of diagnostic nomograms (DN) based on proteomic urinary biomarkers to detect clinically significant prostate cancer.

Urinary peptidomic profile predicts age-related chronic diseases, excessive fibrosis

Oct. 2021

By Marilynn Larkin


NEW YORK (Reuters Health) - Researchers have produced and validated a urinary peptidomic profile (UPP) biomarker that distinguishes healthy from unhealthy aging based on fibrosis and extracellular matrix (ECM) remodeling in patients with chronic diseases.


A consortium of researchers belonging to the Research Institute Alliance for the Promotion of Preventive Medicine (Mechelen, Belgium), Mosaiques-Diagnostics (Hannover, Germany), Hospital, St. Georg (Leipzig, Germany), and the Universities of Hasselt and Leuven in Belgium and other European Research Institutes published today an article in The Lancet Healthy Longevity that shows data underpinning the groundbreaking idea that analysis of a small urine sample provides information on a person’s biological age and the probability of that a person will age healthy.

Revolution in personalised medicine

Symbiosis of diagnostics and therapy

Mosaiques Diagnostics & Therapeutics AG has pursued this goal through intensive research over the last 20 years and has developed a technology to transfer this vision into practice. The technology is now available to detect diseases as early as possible and with unprecedented precision. This is what makes it possible to effectively treat diseases with drug therapies at the earliest timepoint.

Mosaique's clinical proteome analysis enables:

Mosaiques Diagnostics & Therapeutics AG

The mosaiques diagnostics & therapeutics AG was established in Hannover (Germany).

The company’s core competence is the early and reliable detection of diseases enabling personalized medicine during therapy and drug development. The company utilizes diagnostic polypeptide patterns (DiaPat) derived from the fast and accurate analysis of proteins and polypeptides in body fluids (e.g. urine, bile and cerebrospinal fluid).